FDA Approves Fasikl’s Felix NeuroAI Wristband as First AI-Powered Treatment for Essential Tremor

Fasik has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Felix™ NeuroAI™ Wristband. 

This wearable device is designed to support adults with essential tremor by reducing tremor-related functional limitations in the upper limbs.

It causes involuntary shaking, especially in the hands, making everyday tasks such as drinking or dressing difficult. Current treatment options include medication and surgical procedures like deep brain stimulation (DBS) or focused ultrasound. 

However, medicines do not help all patients and often lead to side effects, while surgical methods are invasive and may not be suitable for everyone.

The Felix wristband offers a noninvasive alternative. It is worn on the wrist and connects to Fasikl’s cloud-based AI platform. 

The system adapts in real time to the user’s needs, providing tailored stimulation throughout the day to help manage tremor symptoms. This brain-AI connection allows for continuous adjustment, aiming to improve daily functioning without disrupting the user’s lifestyle.

Fasikl now plans to move ahead with commercial launch preparations, aiming to make the Felix wristband available to the wider essential tremor community as a scalable, noninvasive, and intelligent treatment option.